American Heart Journal
Volume 158, Issue 5 , Pages 777-783, November 2009

Prognostic value of B-type natriuretic peptide for cardiovascular events independent of left ventricular end-diastolic pressure

  • Robert Kevin Rogers, MD, MSCI

      Affiliations

    • University of Utah, Division of Cardiology, Salt Lake City, UT
    • Corresponding Author InformationReprint requests: Robert Kevin Rogers, MD, Division of Cardiology, University of Utah Health Sciences, 30 North 1900 East, Rm 4A100, Salt Lake City, UT 84132-2401.
  • ,
  • Heidi T. May, PhD, MSPH

      Affiliations

    • Intermountain Health Care, Division of Cardiology, Murray, UT
  • ,
  • Jeffrey L. Anderson, MD

      Affiliations

    • University of Utah, Division of Cardiology, Salt Lake City, UT
    • Intermountain Health Care, Division of Cardiology, Murray, UT
  • ,
  • J. Brent Muhlestein, MD

      Affiliations

    • University of Utah, Division of Cardiology, Salt Lake City, UT
    • Intermountain Health Care, Division of Cardiology, Murray, UT

Received 20 May 2009; accepted 3 September 2009.

Background

B-type natriuretic peptide (BNP) correlates with left ventricular (LV) end-diastolic pressure (LVEDP) and predicts cardiovascular events. We sought to determine whether BNP has prognostic value independent of LVEDP.

Methods

Eligible patients were referred for coronary angiography between March 15, 2002, and April 30, 2008, at a single institution. Inclusion criteria were having BNP, LV ejection fraction (EF), and LVEDP measured within 24 hours of the angiogram. The predictive value of BNP for events independent of LVEDP, EF, and other confounders was determined.

Results

The study population (n = 1,059) was followed for a mean of 1.8 ± 1.7 years. The mean age was 63 ± 13 years. The median BNP value was 182 pg/mL; 59% of patients had LVEDP ≥16 mm Hg. B-type natriuretic peptide and LVEDP had a modest but statistically significant correlation (r = 0.24, P < .0001). After adjustment for LVEDP and EF, the hazard ratio for the composite outcome of heart failure admissions and death was 1.37 (1.21-1.55, P < .0001) per unit increase in log BNP. After adjustment for BNP and EF, LVEDP did not predict heart failure admissions and death (hazard ratio 1.05 [0.95-1.10], per 5-mm Hg increase, P = .30). Those with BNP value below the median had longer event-free survival as compared to those with BNP value above the median, regardless of the LVEDP strata (log-rank P < .0001 for LVEDP ≥16 and <16 mm Hg).

Conclusion

B-type natriuretic peptide has prognostic value independent of LVEDP in this cohort with suspected coronary artery disease, suggesting this biomarker is not just a prognostic surrogate for elevated LV filling pressure.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0002-8703(09)00719-4

doi:10.1016/j.ahj.2009.09.002

American Heart Journal
Volume 158, Issue 5 , Pages 777-783, November 2009